Videos

William G. Wierda, M.D., Ph.D., medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses how to best combine and sequence therapies for patients with chronic lymphocytic leukemia (CLL).

A new patient-reported outcomes tool is helping to shift the way end-of-life and depression-related conversations are occurring between patients with multiple myeloma and their health care teams.

Genetic testing – particularly for microsatellite instability (MSI) – is an important step for all patients diagnosed with colorectal cancer.

Now that we're in an era of personalized medicine, patients should not look at statistics and immediately think that they will determine their fate, says Tom Stockwell, patient navigator at the Fibrolamellar Cancer Foundation.

Marina Chiara Garassino, M.D., talks about how immunotherapy agents have vastly improved the treatment field of patients with non-small cell lung cancer.

Carole Brennan Miller, M.D., head of the Cancer Institute at Saint Agnes Hospital, explains what makes people with myeloproliferative neoplasms (MPNs) unique, and why she finds it interesting to work with them.

A myeloproliferative neoplasm survivor and advocate offers advice on how loved ones can support a patient with cancer.

Cristiana Sessa, M.D., of the Oncology Institute of Southern Switzerland, discusses the evolution of how PARP inhibitors are used to treat ovarian cancer.

Susan Leclair, Ph.D., CLS (NCA), retired lab professor at University of Massachusetts, Dartmouth, discusses how moderating an online forum for patients with myeloproliferative neoplasms (MPNs) has inspired her.

Catriona Jamieson, M.D., Ph.D., Professor of Medicine, University of California, San Diego Health Moores Cancer Center, addresses a common myth about clinical trials.